Table 3 Subgroup analysis: baseline demographics of patients with idiopathic pulmonary fibrosis before and after propensity score matching – intensive care unit respiratory hospitalizations requiring mechanical ventilation
| Â | Before propensity score matching | After propensity score matching | ||||
|---|---|---|---|---|---|---|
No Rx (N = 751) | Pirfenidone/Nintedanib (N = 94) | Std. Diff | No Rx (N = 94) | Pirfenidone/Nintedanib (N = 94) | Std. Diff | |
Age group | ||||||
45–64 | 119 (15.8%) | 15 (16.0%) | 0.003 | 19 (20.2%) | 15 (16.0%) | − 0.111 |
65–74 | 248 (33.0%) | 46 (48.9%) | 0.328 | 5 (47.9%) | 46 (48.9%) | 0.021 |
75 +  | 384 (51.1%) | 33 (35.1%) | − 0.328 | 30 (31.9%) | 33 (35.1%) | − 0.068 |
Gender | ||||||
Female | 318 (42.3%) | 26 (27.7%) | − 0.312 | 27 (28.7%) | 26 (27.7%) | − 0.024 |
Male | 433 (57.7%) | 68 (72.3%) | 0.312 | 67 (71.3%) | 68 (72.3%) | 0.024 |
Race | ||||||
White | 470 (62.6%) | 58 (61.7%) | − 0.018 | 61 (64.9%) | 58 (61.7%) | − 0.066 |
Black | 75 (10.0%) | 6 (6.4%) | − 0.132 | 3 (3.2%) | 6 (6.4%) | 0.150 |
Hispanic | 87 (11.6%) | 15 (16.0%) | 0.127 | 13 (13.8%) | 15 (16.0%) | 0.060 |
Other | 119 (15.8%) | 15 (16.0%) | 0.003 | 17 (18.1%) | 15 (16.0%) | − 0.057 |
Census region | ||||||
Midwest | 178 (23.7%) | 27 (28.7%) | 0.114 | 30 (31.9%) | 27 (28.7%) | − 0.069 |
Northeast | 113 (15.0%) | 9 (9.6%) | − 0.167 | 12 (12.8%) | 9 (9.6%) | − 0.101 |
South | 402 (53.5%) | 50 (53.2%) | − 0.007 | 43 (45.7%) | 50 (53.2%) | 0.149 |
West | 58 (7.7%) | 8 (8.5%) | 0.029 | 9 (9.6%) | 8 (8.5%) | − 0.037 |
Baseline comorbidities | ||||||
Cardiac Arrhythmia | 350 (46.6%) | 30 (31.9%) | − 0.303 | 30 (31.9%) | 30 (31.9%) | 0.000 |
Congestive Heart Failure | 337 (44.9%) | 28 (29.8%) | − 0.315 | 25 (26.6%) | 28 (29.8%) | 0.071 |
Other Chronic Pulmonary Conditions | 604 (80.4%) | 65 (69.1%) | − 0.261 | 70 (74.5%) | 65 (69.1%) | − 0.118 |
Depression | 165 (22.0%) | 22 (23.4%) | 0.034 | 23 (24.5%) | 22 (23.4%) | − 0.025 |
Diabetes | 310 (41.3%) | 36 (38.3%) | − 0.061 | 38 (40.4%) | 36 (38.3%) | − 0.043 |
Hypertension | 604 (80.4%) | 65 (69.1%) | − 0.261 | 64 (68.1%) | 65 (69.1%) | 0.023 |
Pulmonary Circulation Disorder | 216 (28.8%) | 27 (28.7%) | − 0.001 | 25 (26.6%) | 27 (28.7%) | 0.047 |
Renal Failure | 184 (24.5%) | 13 (13.8%) | − 0.273 | 14 (14.9%) | 13 (13.8%) | − 0.030 |
Solid Tumor without Metastasis | 119 (15.8%) | 10 (10.6%) | − 0.154 | 9 (9.6%) | 10 (10.6%) | 0.035 |
Valvular Disease | 207 (27.6%) | 19 (20.2%) | − 0.173 | 20 (21.3%) | 19 (20.2%) | − 0.026 |
Elixhauser comorbidity index | ||||||
Mean (SD) | 6.3 (3.3) | 4.9 (3.0) | − 0.414 | 5.1 (3.2) | 4.9 (3.0) | − 0.061 |
Median | 6.0 | 5.0 | −  | 4.5 | 5.0 | −  |
Q1, Q3 | 4.0, 9.0 | 3.0, 6.0 | −  | 3.0, 8.0 | 3.0, 6.0 | −  |
N hospitalizations in baseline | ||||||
0 | 383 (51.0%) | 61 (64.9%) | 0.284 | 54 (57.4%) | 61 (64.9%) | 0.153 |
1 | 211 (28.1%) | 24 (25.5%) | − 0.058 | 25 (26.6%) | 24 (25.5%) | − 0.024 |
2 +  | 157 (20.9%) | 9 (9.6%) | − 0.319 | 15 (16.0%) | 9 (9.6%) | − 0.192 |
Year of hospitalization | ||||||
2015 | 176 (23.4%) | 12 (12.8%) | − 0.280 | 10 (10.6%) | 12 (12.8%) | 0.066 |
2016 | 204 (27.2%) | 30 (31.9%) | 0.104 | 29 (30.9%) | 30 (31.9%) | 0.023 |
2017 | 200 (26.6%) | 27 (28.7%) | 0.047 | 31 (33.0%) | 27 (28.7%) | − 0.092 |
2018 | 171 (22.8%) | 25 (26.6%) | 0.089 | 24 (25.5%) | 25 (26.6%) | 0.024 |
Reason for admission | ||||||
Diseases of respiratory system | 562 (74.8%) | 47 (50.0%) | − 0.530 | 40 (42.6%) | 47 (50.0%) | 0.150 |
Diseases affecting the interstitium | 144 (19.2%) | 44 (46.8%) | 0.615 | 49 (52.1%) | 44 (46.8%) | − 0.107 |
All other reasons | 45 (6.0%) | 3 (3.2%) | − 0.134 | 5 (5.3%) | 3 (3.2%) | − 0.106 |
Pulmonologist visit | 408 (54.3%) | 80 (85.1%) | 0.709 | 85 (90.4%) | 80 (85.1%) | − 0.162 |
Smoker | 414 (55.1%) | 46 (48.9%) | − 0.124 | 52 (55.3%) | 46 (48.9%) | − 0.127 |
Steroid use | 420 (55.9%) | 69 (73.4%) | 0.371 | 69 (73.4%) | 69 (73.4%) | 0.000 |
Oxygen use | 484 (64.4%) | 83 (88.3%) | 0.433 | 74 (78.7%) | 83 (88.3%) | 0.053 |